Schedule of revenue per type of good or service


		For the year ended December 31
in 000€		2025		2024		2023
Software revenue (non-medical)		40,907		43,899		44,442
Software revenue (medical)		37,299		33,756		31,700
Medical devices and services		96,941		82,602		69,676
Manufacturing		92,486		106,508		110,310
Total		267,633		266,765		256,127


		For the year ended December 31
in 000€		2025		2024		2023
Purchase of goods and services		(49,207)		(52,576)		(53,747)
Amortization and depreciation		(11,890)		(11,607)		(11,298)
Payroll expenses		(53,719)		(51,705)		(46,678)
Work in Progress		133		(52)		727
Total		(114,684)		(115,940)		(110,996)

Schedule of sales and marketing expenses


		For the year ended December 31
in 000€		2025		2024		2023
Purchase of goods and services		(10,810)		(10,949)		(10,437)
Amortization and depreciation		(2,162)		(2,319)		(2,285)
Payroll expenses		(48,620)		(48,328)		(45,100)
Other		—		(24)		—
Total		(61,591)		(61,620)		(57,822)

Schedule of net other operating incomes expenses


		For the year ended December 31
in 000€		2025		2024		2023
Government grants		5,282		4,913		4,853
Amortization intangibles purchase price allocation⁽¹⁾		(3,078)		(3,326)		(4,012)
Allowance for doubtful debtors		(418)		(95)		(448)
Tax credits		913		1,246		1,360
Arbitration settlement		—		—		(5,189)
Impairment of intangible assets (Note 6) and PP&E (Note 7)		—		—		(3,054)
Impairment of goodwill (Note 5)		—		—		(1,175)
Other		1,090		1,485		1,141
Total		3,789		4,223		(6,524)

(1)

The Amortization intangibles purchase price allocation relates to the amortization of intangibles assets recognized in purchase price allocations from the acquisitions of Materialise Motion, Engimplan, ACTech, E-Prototypy, OrthoView, Cenat, Link3D, Identify3D and FEops NV. As of December 31, 2025, the remaining amortization period for the acquired customer relationships is 2.1 years for Materialise Motion and 11.0 years for ACTech. The customer relationships acquired in Engimplan, E-Prototypy, OrthoView and Cenat are fully amortized. As of December 31, 2025, the remaining amortization period for the acquired technology and contracts is 1.8 years for Materialise Motion and 5.6 years for FEops NV. The amortization of these assets does not directly relate to specific functional areas such as cost of sales or research and development.

Schedule of financial expenses


		For the year ended December 31
in 000€		2025		2024		2023
Interest expense		(1,712)		(1,299)		(1,751)
Foreign exchange losses		(3,539)		(1,310)		(1,770)
Other financial expenses		(365)		(360)		(344)
Total		(5,616)		(2,969)		(3,865)

Schedule of breakdown of the tax expense


		As of December 31,
in 000€		2025		2024		2023
Current income tax		(934)		(1,861)		(2,355)
Deferred income taxes		1,363		1,128		2,277
Total income taxes for the period		429		(733)		(78)

Schedule of relationship between tax expense and accounting profit


		For the year ended December 31
in 000€		2025		2024		2023
Profit (loss) before taxes		7,287		14,139		6,772
Income tax at statutory rate of 25%		(1,822)		(3,535)		(1,693)
Effect of different local tax rate		159		(294)		(416)
Tax adjustments to the previous period		313		125		(63)
Non-deductible expenses		(330)		(301)		(324)
Research and development tax credits		220		517		203
Innovation income deduction		2,984		3,325		2,560
Non recognition of deferred tax asset		(2,969)		(1,292)		(1,815)
Recognition of previously unrecognized tax losses		1,407		221		1,186
Non-taxable income		877		574		450
Use of previous years’ tax losses and tax credits (or deductible temporary differences) for which no deferred tax assets were recognized		—		462		—
Taxes on other basis		(409)		(348)		(232)
Other		(1)		(187)		66
Income tax benefit (expense) as reported in the consolidated income statement		429		(733)		(78)